KBC Group
ROIV icon

KBC Group’s Roivant Sciences ROIV Stock Holding History

KBC Group’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$325K Sell
11,732
-802
-6% -$20.6K ﹤0.01% 854
2025
Q4 		$272K Buy
12,534
+1,867
+18% +$36.8K ﹤0.01% 813
2025
Q3 		$161K Hold
10,667
– – ﹤0.01% 1005
2025
Q2 		$120K Sell
10,667
-5,609
-34% -$60.8K ﹤0.01% 1095
2025
Q1 		$164K Buy
16,276
+402
+3% +$4.35K ﹤0.01% 1178
2024
Q4 		$188K Buy
15,874
+5,839
+58% +$69K ﹤0.01% 1165
2024
Q3 		$116K Hold
10,035
– – ﹤0.01% 1193
2024
Q2 		$106K Buy
10,035
+3,268
+48% +$35.8K ﹤0.01% 1132
2024
Q1 		$71K Hold
6,767
– – ﹤0.01% 1328
2023
Q4 		$76K Sell
6,767
-774
-10% -$7.54K ﹤0.01% 1238
2023
Q3 		$88K Buy
+7,541
New +$85.3K ﹤0.01% 1068

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

KBC Group's ROIV Position: Q1 2026 in Review

KBC Group reduced its Roivant Sciences (ROIV) stake by 6.4% in Q1 2026, selling an estimated $20.6K and leaving 11,732 shares worth $325K. The position accounts for ﹤0.01% of the portfolio, ranked #854.

KBC Group first reported a position in ROIV in Q3 2023 and has held it in 11 quarters since. 440 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

  • KBC Group held 11,732 shares of Roivant Sciences worth $325K as of Q1 2026.
  • KBC Group sold 802 Roivant Sciences shares in Q1 2026, an estimated $20.6K.
  • Roivant Sciences made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #854 holding.
  • KBC Group first reported a position in Roivant Sciences in Q3 2023 and has held it in 11 quarters since.
  • 440 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.